12th Annual Meeting of Korean Society of Medical Oncology &
2019 International Conference
November 7 (Thu) - 8 (Fri), 2019 Seoul Dragon City, Seoul, Korea
www.ksmo2019.org

KSMO 2019
Building up Team Science to Cure Cancer!

• **Name:** Jeeyun Lee, MD

• **Current Position: Associate Professor**

• **Country: South Korea**

• **Educational Background:**

2004	Ph.D degree in Medicine, Sungkyunkwan University School of Medicine
2001	Master's degree in Medicine, Sungkyunkwan University School of Medicine
1999	MD, Ewha University School of Medicine

• **Professional Experience:**

2014.3 - present ***Associate Professor***, Division of Hem/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine

2010.2 – 2014.2 ***Assistant Professor***, Division of Hem/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine

2006.3 – 2010.2 ***Clinical Assistant Professor***, Division of Hem/Oncology, Samsung Medical Center

2006.7 – 2008. 1 ***Visiting Scientist***, Sidney Kimmel Cancer Center, San Diego, CA, USA

2005.3 – 2006. 2 ***Senior Research Fellow***, Clinical Trial Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

2005.7 completed ***AACR Workshop in Cancer Research***: Molecular Biology in Clinical Oncology, Aspen, CO, USA

2004.8 completed ***Australia and Asia Pacific Clinical Oncology Research Development Workshop***: A Workshop in Effective Clinical Trials Design

2004.3 – 2006.2 ***Clinical Fellowship in Hematology-Oncology,*** Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

2000.3 – 2004.2 ***Residency in Internal Medicine***, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

1999.3 – 2000.2 ***Internship***, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

• **Main Scientific Publications:**

1. Lee JK et al (**as a co-corresponding author**) Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. ***Nature Genetics*** 2018 Oct;50

2. Kim ST et al (**as a co-corresponding author**) Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. ***Nature Medicine*** 2018 July 16 epub

12th Annual Meeting of Korean Society of Medical Oncology &
2019 International Conference
November 7 (Thu) - 8 (Fri), 2019   Seoul Dragon City, Seoul, Korea
www.ksmo2019.org

KSMO 2019
Building up Team Science to Cure Cancer!

3. Kim ST et al (**as a corresponding author**) Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2-positive gastric cancer patients. *Annals of Oncology*. 2018 Apr 1;29(4):1037-1048

4. Kim ST et al **(as a corresponding author)** Rapamycin-insensitive companion of mTOR (RICTOR) Amplification Defines a Subset of Advanced Gastric Cancer and is Sensitive to AZD2014-mediated mTORC1/2 Inhibition. *Annals of Oncology*. 2017 Mar 1;28(3):547-554

5. Kim ST, et al (**as a corresponding author**) Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis. *JCO Precision Oncology* 2017

6. Kim ST, Kim KM, Kim NKD, Park JO, Ahn S, Yun JW, Kim KT, Park SH, Park PJ, Kim HC, Sohn TS, Choi DI, Cho JH, Heo JS, Kwon W, Lee H, Min BH, Hong SN, Park YS, Lim HY, Kang WK, Park WY, **Lee J. (as a corresponding author**) Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials. *Oncologist* 2017 Oct;22(10):1169-1177

7. R Cristescu, **Lee J,** Nebozhyn M, Kim KM et al**. (co-first author)** Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. *Nature Medicine*. 2015 May;21(5):449-56